Treatment Center of Tianjin Hematology Hospital

Leukemia Diagnostic and Treatment Center

Leukemia Diagnostic and Treatment Center is a department that mainly admits and treats all kinds of acute leukemia, chronic granulocytic leukemia and other myeloproliferative diseases. Divided into two wards, **** there are more than 90 treatment beds (including 15 thousand laminar flow isolation beds; general wards have single rooms, 2 rooms, 3 rooms). There are 3 chief physicians, 1 deputy chief physician and 6 attending physicians. There are more than 30 nursing staff, including 1 deputy chief nurse and 3 chief nurses. The Leukemia Diagnostic and Treatment Center takes the pathogenesis of leukemia, chemotherapy, and analysis of prognostic factors as the main research objects, and is the leader of leukemia chemotherapy in the country. Here, the identification of a new subtype of acute granulocytic leukemia-M2b and its characterization were carried out; in the 1980s, it was the first to complete the comparison between the domestic chemotherapeutic agent hypertriglyceride (HHT) + cytarabine (HA regimen) and the international first-line acute myeloid leukemia (AML) chemotherapy regimen of Zoerythromycin + cytarabine (DA), and established the position of HA regimen as the first-line regimen of AML chemotherapy in the country. regimen's status. On this basis, the efficacy observation of HA-based three-drug combination chemotherapy regimen (HAD, HAM, HAA and HAE) in the treatment of AML was explored, and a set of systematic treatment program was formulated with promising results. Statistical analysis of the efficacy of 243 patients with primary and initial AML in the last 12 years***: the complete remission (CR) rate reached 76.5%; the median disease-free survival (DFS) of patients in complete remission was 29.6 (0.5-153) months, the 3-year DFS rate was 46.2%, and the 5-year DFS rate was 43.1%. the median overall survival (OS) of 243 patients was 18.6 (0.5 -154) months, with a 3-year OS rate of 37.7% and a 5-year OS rate of 32.7%. The 184 patients were categorized into good, intermediate, and poor groups based on the karyotype results, and the CR rate, median DFS, and OS of the three groups were 95.8%, 87 months, and 89 months in the good karyotype group, 80%, 13 months, and 19 months in the intermediate karyotype group, and 43.8%, 0.5 months, and 11 months in the poor karyotype group, respectively. The 3-year DFS rate and 5-year DFS rate of the three groups were 62.1% and 58.5% in the good karyotype group, 35.4% and 33.7% in the intermediate karyotype group, and 18.8% and 18.8% in the poor karyotype group, respectively. The 3-year OS rate and 5-year OS rate of the three groups were 61.4% and 57.9% in the good karyotype group, 35.7% and 32.3% in the intermediate karyotype group, and 18.8% and 18.8% in the poor karyotype group, respectively. In order to adapt to the national and public situation, a reasonable treatment cycle after AML remission was explored on the basis of the above summary. Recently, on the basis of the above experience, the whole set of treatment protocols for AML has been further improved and refined, grouping treatment according to chromosomal karyotypes and emphasizing the application of high-dose chemotherapy, with a view to reducing the occurrence of refractory drug-resistant cases, shortening the treatment cycle, and increasing the long-term survival rate. Our center was also the first to conduct research on refractory drug-resistant leukemia in China, and the first clinical study of CSA reversal of drug resistance in China was completed here. Recently, the treatment of refractory drug-resistant AML has been explored with FLAG, MAC and AAC regimens, and preliminary efficacy has been achieved. In addition, many valuable experiences of leukemia treatment observation have been summarized: for example, the significance of routine bone marrow aspiration during induction chemotherapy for acute leukemia, the experience of treatment of heterogeneous acute leukemia, how to prevent vascular damage by chemotherapeutic drugs, and so on.

These valuable therapeutic experiences have all been promoted to different degrees in China, and have solved many puzzling problems in the domestic hematology community. Adult acute lymphoblastic leukemia (ALL) has always been a difficult problem for the domestic hematology community, with poor therapeutic effects. On the basis of summarizing past experience, the Leukemia Center has formulated a complete set of treatment protocols suitable for China's national conditions with reference to international treatments, and has constantly revised and improved them in clinical practice (forming the IH2003 protocol). Statistically analyzing 149 patients over the past 10 years, the overall complete remission (CR) rate of induction therapy was 93.7%. The median disease-free survival (DFS) was 13 (1-97) months, and the median OS was 17.5 (1-97) months. 3-year and 5-year DFS amounted to 34.1% and 20.3%, respectively; and OS was 44.2% and 36.5%, respectively. For Ph(BCR/ABL)-positive cases with very poor prognosis, (patients without bone marrow source), combination chemotherapy with Gleevec or interferon was used to improve CR rate and prolong survival. Leukemia Diagnostic and Treatment Center has a nursing team with strong sense of responsibility, excellent technology and rich experience, insisting on patient-centered work, carrying out new technologies such as PICC and implantable infusion port, attaching great importance to business learning and strengthening life care to ensure the smooth progress of clinical treatment. Leukemia Diagnosis and Treatment Center is an important part of national key discipline point and national oncology drug clinical pharmacology base and doctoral point. In order to be in line with international standards, it has taken the lead in carrying out FAB typing, MICM typing and WHO typing diagnosis of acute leukemia. He has edited or participated in the writing of several hematology monographs. He has completed the clinical trials of many drugs, such as Anacrine, Methylisoindigo, Desmethoxazolam, Pemetrynase, Compound Yellow Dye Tablet, etc. He has also participated in the international multi-center clinical trial study of AMN107, etc., and gained a lot of valuable experience, which has made an important contribution to the popularization and application of these drugs in our country.

While making achievements in clinical work, the center attaches great importance to basic research and clinical application of basic research. It has carried out pharmacokinetic studies and in vitro drug sensitivity experiments in acute leukemia, micro-residual leukemia studies, leukemia oncogene and leukemia stem cell studies.

The center has experienced experts with deep academic attainments, as well as young and middle-aged professionals with rich clinical experience who have returned from abroad, and a team of energetic and diligent doctoral students, master's degree students, and young physicians. Meanwhile, we also have a nursing team with rich experience in professional nursing, skillful technique and good service attitude. We are willing to provide first-class medical and nursing services for patients with leukemia and other blood diseases at home and abroad.

Anemia Diagnostic and Treatment Center

Anemia Diagnostic and Treatment Center mainly carries out research on the pathogenesis of erythrocyte system diseases, new techniques and strategies of diagnosis and treatment, and admits and treats all kinds of bone marrow hematopoietic failure syndrome, congenital and acquired hemolytic anemia, erythrocytosis, all kinds of difficult diseases of the blood system accompanied by anemia, and all kinds of internal medicine diseases mainly manifested by anemia.

Anemia Diagnostic and Treatment Center consists of two wards, now **** there are 103 beds, including 81 general beds, 20 beds with 1,000-level laminar flow, and 2 beds with 100-level laminar flow. Every year, it receives about 1,000 hospitalized patients from all over the country, and the bed utilization rate is over 95%. The diagnosis and differential diagnosis of anemia is standardized and accurate, and has long been renowned. The therapeutic effect of severe aplastic anemia has always been in the leading position in China, and the effective rate of treatment with anti-thymocyte globulin is as high as more than 70%, and in recent years, it is the first one to explore and carry out a new method of high-dose cyclophosphamide treatment for severe remittance in China, and the initially-treated patients have got 80% of the efficacy and no serious toxic side effects have been detected, so that many patients who have difficulties in financing have been saved. This has enabled many patients with financial difficulties to receive treatment. The use of 1,000-level laminar flow wards has reduced the incidence of infection, thus reducing the overall cost of treatment. In terms of hemolytic diseases, we have diagnosed and treated a variety of common and rare congenital or acquired hemolytic anemia, such as P5'N deficiency, thermally unstable anisocytosis, etc., which has led to the reasonable diagnosis and treatment of many patients with unclear or misdiagnosis. In terms of myelodysplastic syndromes, myelofibrosis and other intractable hematologic diseases, the center keeps abreast of domestic and international medical developments, grasps new medicines and therapies, and strives to achieve the best therapeutic effects. The center is the first of its kind in the diagnosis of various difficult diseases of the blood system, and has diagnosed a variety of rare diseases at home and abroad, such as congenital dyserythropoietic anemia, antiphospholipid syndrome manifesting as hemolytic anemia, large granular lymphocytic leukemia, thrombotic thrombocytopenic purpura, NK/T-cell lymphoma/leukemia, and so on, which has made the patients who have been transferred to a lot of hospitals without diagnosis to have their diagnosis clarified.

Analytic anemia is the most common form of anemia in the world.

Anemia Treatment Center has a highly skilled and ethical clinical medical team,*** there are 75 medical staff, 20 physicians, nursing staff 55. Senior technical title 4 people, intermediate technical title 15 people, junior technical title 56 people. Physician team with a doctorate degree of 7 people, master's degree of 7 people, master's degree tutor 2 people, in the master's degree 15 people. Nursing team with college and college education accounted for more than 90% of all nursing staff. Many members of the department have been awarded the title of "Honest Individual", and the department itself has been awarded the title of "Honest Department", "Advanced Collective of Spiritual Civilization", "Youth Civilization Model", and "Youth Civilization Model" at the municipal level of Tianjin. The department itself has also been named "Integrity Department", "Advanced Group of Spiritual Civilization" at the institutional level, "Youth Civilization" at the municipal level in Tianjin.

The center is responsible for "research on the biological characteristics of hematopoietic stem cells in severe aplastic anemia", "research on the correlation between the identification and typing of chronic aplastic anemia as well as the material basis of cellular molecular biology". We are also exploring new treatment methods and strategies.

Hematopoietic Stem Cell Transplantation Center

Hematopoietic Stem Cell Transplantation Center's research aims to improve the efficacy of hematopoietic stem cell transplantation in the treatment of various blood disorders, and carries out the research on the optimal pre-treatment plan for patients with different types of disorders, effective prediction of recurrence of the disease, and effective preventive plan, as well as the pathogenesis and the effective prediction method of the occurrence of acute and chronic transplantation diseases after the transplantation of allogeneic hematopoietic stem cells. Effective prediction methods and treatment methods for the occurrence of graft disease, research on effective prevention and treatment methods for invasive aspergillosis after hematopoietic stem cell transplantation, and research on effective methods for in vitro purification of autologous grafts.

The Hematopoietic Stem Cell Transplantation Center consists of two wards with 72 general beds, 12 100-level laminar flow beds and 12 1,000-level laminar flow beds. It admits and treats patients with acute and chronic leukemia, severe aplastic anemia, myelodysplastic syndromes, myeloproliferative disorders, and various kinds of difficult and complicated hematological diseases.

Hematopoietic Stem Cell Transplantation Center was established in the 1980s, and was the first in China to carry out autologous bone marrow transplantation for the treatment of acute leukemia, and conducted systematic research on the classical pretreatment programs of systemic radiotherapy + cyclophosphamide, and Mariline + cyclophosphamide, which proved that the nationals are equally suitable for pre-transplantation pretreatment with international standard dosage pretreatment programs. In addition, we have made remarkable achievements in the fields of allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, hemizygous compatible hematopoietic stem cell transplantation and hematological disorders, etc. The long-term disease-free survival rate of transplantation for patients with common hematological disorders such as various types of acute and chronic leukemia, severe aplastic anemia, lymphoma, multiple myeloma, myelodysplastic syndrome, etc., has reached the advanced level in the international arena, and some of them have reached the international The long-term disease-free survival rate of patients with common hematologic diseases such as aplastic anemia, lymphoma and myelodysplastic syndrome has reached the international advanced level, and some of them have reached the international leading level.

HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation, unrelated donor hematopoietic stem cell transplantation, hemizygous hematopoietic stem cell transplantation, umbilical cord blood hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, and hemizygous alternating irradiation therapy have been carried out for the treatment of patients with acute and chronic leukemias, severe aplastic anemia, paroxysmal sleep hemoglobinuria, lymphomas, multiple myeloma, and myelodysplastic syndrome. anomalous syndrome, and other hematologic diseases. By August 2007, 532 patients with various blood diseases have been transplanted, and the long-term disease-free survival rate of HLA-matched sibling-donor allogeneic HSCT for chronic granulocytic leukemia reaches 80%, and the long-term disease-free survival rate of HLA-matched sibling-donor allogeneic HSCT for acute myeloid leukemia and acute lymphoblastic leukemia in the first remission period reaches 60%-65%; The long-term disease-free survival rate of HLA-matched sibling donor allogeneic HSCT for myelodysplastic syndromes reaches 47%; the long-term disease-free survival rate of HLA-matched sibling donor allogeneic HSCT for patients with aplastic anemia of severe type reaches 81%; the long-term disease-free survival rate of autologous HSCT for acute non-lymphoblastic leukemia in the first remission period reaches 55%, and the long-term disease-free survival rate of autologous HSCT for acute non-lymphocytic leukemia in the first remission period reaches 55%. The long-term disease-free survival rate of acute lymphoblastic leukemia in first remission treated with autologous hematopoietic stem cell transplantation reached 60%; the long-term disease-free survival rate of acute lymphoblastic leukemia in first complete remission treated with hemihypoplasia alternating radiotherapy reached 42%.

The Hematopoietic Stem Cell Transplantation Center has a technically responsible, skilled and experienced medical team with 82 medical and nursing staff, including 3 chief physicians, 2 deputy chief physicians, 6 attending physicians, 15 residents, 9 doctoral degree holders, 6 master's degree holders, 2 deputy chief nurses, and 70 medical and nursing technicians, with 1 doctoral supervisor, 1 master's supervisor, and 9 doctoral students. 1 person, in the study of doctoral students 9, in the study of master's degree students 4.

Medical staff adhere to the patient-centered, efforts to improve the patient's medical environment, to improve the quality of service, improve the efficacy of treatment, to ensure medical safety for the purpose. At the same time, they actively cooperate with Tianjin Red Cross to carry out publicity activities for hematopoietic stem cell donation and assist Tianjin Red Cross in collecting hematopoietic stem cells for voluntary donors for transplantation, and more than 30 medical, nursing and technical personnel of the Transplantation Center have actively enrolled in the registration for hematopoietic stem cell donation.

The Hematopoietic Stem Cell Transplantation Center carries out research on in vitro purification of hematopoietic stem cell grafts, successively adopts monoclonal antibody, INW2 and other in vitro purification treatment, CD34-positive cell sorting and other methods to purify hematopoietic stem cell grafts, and researches on the appropriate pre-treatment plan, intensive consolidation and strengthening treatment before transplantation, and post-transplantation maintenance chemotherapy and immunotherapy, so as to make the therapeutic efficacy of autologous transplantation for acute leukemia reach the international leading level. The efficacy of autologous transplantation has reached the international leading level. In addition, we have conducted systematic research on the high-risk factors for the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, predictive indicators, and effective prevention and treatment programs; risk factors for the recurrence of leukemia after transplantation, detection of residual disease, and effective treatment programs for early recurrence after transplantation; and effective prevention and treatment strategies for post-transplantation complications, such as invasive fungal infections, interstitial pneumonitis, and hepatic vein occlusive disease, which have yielded good He has achieved good results. Study on risk factors and prevention strategies of invasive aspergillosis".

The Center for Thrombosis and Hemostasis

The Center for Thrombosis and Hemostasis is mainly engaged in the research of new strategies for the treatment of thrombotic and hemorrhagic diseases, the physiopathological characteristics of megakaryocytes and platelets, and the regulatory mechanisms of neovascularization.

The Thrombostasis Center has 46 beds. It admits and treats all kinds of hereditary and acquired bleeding disorders, and receives referrals from all over the country for all kinds of rare and difficult cases.

The center has 2 chief physicians, 2 attending physicians, 4 residents; 13 nursing staff, 1 doctoral supervisor, 10 doctoral students and 5 master's students.

The Thrombostasis Center is the executive arm of the World Federation of Hemophilia's national member unit (China), and is the leader of the collaborative network of China's hemophilia diagnostic and treatment centers. In the prevention and treatment of hemophilia, it is responsible for organizing and translating the hemophilia education manual***4 volumes and popular science books such as Living with haemophilia by Dr. Peter Jones, medical consultant of the World Federation of Hemophilia, and distributing them to hemophiliacs free of charge. As the leader of the group, with the financial support from the World League of Hemophilia, we are specifically responsible for organizing and implementing the national hemophilia registration, which is now going on smoothly.

The Thrombostasis Center was the first in the world to discover two genetic polymorphism loci with high heterozygosity in the coagulation factor IX gene in Chinese. It is the first time in the world to discover that the serum leptin level of chronic ITP patients is higher than that of normal people, and that CD8+ T cells of chronic ITP patients have Tc1 polarization, which may be due to the down-regulation of GATA-3. The above results have been published in SCI journals abroad. Currently, he is responsible for the research on "The role of DNA methylation in the pathogenesis of chronic ITP", "The relationship between epigenetic factors and ITP", "The role of epigenetic factors in the pathogenesis of chronic ITP", "The role of epigenetic factors in the pathogenesis of chronic ITP" and "The role of epigenetic factors in the pathogenesis of chronic ITP". ", "Precise diagnosis and targeted intervention in idiopathic thrombocytopenic purpura", "Bayer Hemophilia Award (Clinical scholarship award, 2007) ", "Study on the relationship between the reduced number and dysfunction of endothelial progenitor cells and the development of atherosclerosis", "Basic research on attenuated Salmonella as a gene carrier for oral treatment of hemophilia B", "Investigation of thrombophilia in the Chinese population", NNHF grant: Improve the diagnosis, treatment and awareness of hemophilia in China through screening and education. (2007.1-2009.12), and NNHF grant: Improve the diagnosis, treatment and awareness of hemophilia in China through screening and education.

Hematology Emergency Center

The Hematology Emergency Center is an important place for diagnosis and rescue of patients with hematology-related emergencies, critical illnesses and serious illnesses.

The Hematology Emergency Center has more advanced automatic analysis of electrocardiogram, multi-parameter cardiac monitor, ventilator, defibrillator, gastric lavage machine, surgical bag, all kinds of puncture drainage, all kinds of bandaging and carrying the stretcher used, and oxygen absorption, suction equipment. There is one emergency room and 16 hospital beds. It carries out emergency diagnosis and treatment of hematology diseases (red blood cell diseases, white blood cell diseases, coagulation diseases, etc.), rescue of critically ill patients, observation of emergency patients and all outpatients' component blood transfusion, anti-infection treatment, small-dose chemotherapy, intrathecal injection and other treatments.

The Hematology Emergency Center has a responsible, skilled and experienced medical team consisting of 2 chief physicians, 3 attending physicians, 4 senior residents, 1 deputy chief nurse, 4 chief nurses, 9 nurse practitioners and 1 nurse. The medical and nursing staff have received formal training in first aid knowledge, have rich experience in clinical hematology emergency treatment, accurate diagnosis, rapid response and decisive measures. It is a hard-working, united and cooperative team.

Myelodysplastic Syndrome (MDS) Diagnostic and Treatment Center

Myelodysplastic Syndrome Diagnostic and Treatment Center focuses on new strategies for the diagnosis and treatment of myeloid malignant tumors such as myelodysplastic syndromes, myeloproliferative disorders and acute myeloid leukemia.

The ward is equipped with 49 beds, including 10 beds in thousand-level laminar flow isolation. The diagnosis and treatment of myeloid malignant diseases such as myelodysplastic syndromes, myeloproliferative diseases and acute myeloid leukemia have reached the international advanced level. The center has 2 chief physicians, 1 deputy chief physician, 3 attending physicians, 6 residents, 19 nursing staff, 1 doctoral supervisor, 4 doctoral students and 7 master's students.

The center takes the lead in carrying out WHO typing diagnosis of myelodysplastic syndromes and individualized treatment according to the international prognostic score system in China, and the solution of cyclosporine combined with reaction stopping for the treatment of myelodysplastic syndromes in the low-risk group proposed by the center has been popularized and used nationwide. Myelodysplastic syndromes with i(17)(q10), t(1;3)(p36;q21) and der(1;7)(q10;p10), which were proposed by the center as independent clinicopathogenetic diseases, have been basically recognized by international counterparts.

Rare myeloproliferative disorders such as 8p11 syndrome and chronic eosinophilic leukemia with periodic fluctuations in peripheral blood were reported for the first time in China. He has conducted systematic research on laboratory features such as clinical and genetic alterations of chronic eosinophilic leukemia/hypereosinophilic syndrome, and was the first in China to carry out the treatment of chronic eosinophilic leukemia by Gleevec, and conducted in-depth research on the mechanism of its efficacy.

For the first time in China, it was proposed that the proportion of leukemia cells during induction therapy for acute myeloid leukemia is an independent prognostic indicator of its prognosis, and the treatment plan can be adjusted accordingly. The first clinical series of systematic treatment of acute promyelocytic leukemia in China was reported, with a 5-year disease-free survival rate of 82%, which is at the international level.

Systematic research on genetic susceptibility genes of myeloid tumors has confirmed that myelodysplastic syndromes, chronic granulocytic leukemia, and acute myeloblastic cells have different genetic susceptibility backgrounds. We are the first in China to carry out pharmacogenomics to guide individualized treatment. This strategy can further improve clinical efficacy, reduce clinical adverse drug reactions and save medical costs.

Lymphoma Diagnostic and Treatment Center

Lymphoma Diagnostic and Treatment Center is a diagnostic, therapeutic and research center for malignant lymphoma, multiple myeloma, adult acute lymphoblastic leukemia and chronic lymphocytic leukemia and other malignant lymphoproliferative disorders (collectively referred to as lymphomas in the 2001 classification of WHO). It conducts research on the pathogenesis, pathological diagnosis, clinical diagnosis, and clinical treatment techniques of malignant lymphomas.

The center consists of two wards, i.e. conventional treatment ward and intensive treatment and transplantation ward. There are 72 beds in the center, including 46 beds in the conventional treatment ward and 26 beds in the intensive treatment and transplantation ward, including 5 beds with 100-level laminar flow and 5 beds with 1,000-level laminar flow. It admits and treats patients with malignant lymphoma, multiple myeloma, adult acute lymphoblastic leukemia and chronic lymphocytic leukemia and other malignant lymphoproliferative diseases.

Malignant lymphoma (ML): individualized treatment strategies and protocols based on standardization are designed according to the patient's pathological type, stage, and prognostic score, and comprehensive treatment including conventional chemotherapy, immunochemotherapy, intense chemotherapy, and autologous or allogeneic hematopoietic stem cell transplantation is performed. In recent years, we have reported the largest series (more than 150 cases) of high-risk advanced aggressive non-Hodgkin's lymphoma (NHL) invading the bone marrow in China, and the expected 5-on-5 disease-free survival of patients with B-cell NHL using CD20 monoclonal antibody in combination with intensive therapy (immunochemotherapy) or autologous hematopoietic stem cell transplantation reached more than 65%, and for T-cell NHL with very poor prognosis using intense chemotherapy after the induction of The 5-year disease-free survival of autologous hematopoietic stem cell transplantation patients also reached more than 40%.

Multiple myeloma (MM): At present, our center has become one of the largest and highest diagnostic and treatment centers for multiple myeloma in China, and its diagnostic and therapeutic level has reached the international advanced level. Since 2003, autologous hematopoietic stem cell transplantation has been used as part of the first-line treatment for patients aged ≤60 years, and the BDHMM03 protocol has been designed for prospective clinical studies. Currently, the remission rate (≥partial remission) of primary MM induction therapy reaches more than 80%, of which the complete or near-complete remission rate (≥nCR) reaches more than 40%, whereas the complete remission rate of patients with autologous hematopoietic stem cell transplantation reaches more than 60%. The median survival of MM diagnosed and treated at the center after 2003 has exceeded 42 months, which is significantly improved from 27 months in 2002 and has reached the international advanced level in the same period.

Adult acute lymphoblastic leukemia (ALL): Treatment of adult acute lymphoblastic leukemia is the traditional area of strength of the Lymphoma Center. Through more than ten years of research, we have explored a complete set of standardized induction of remission, early sequential intensive treatment consolidation followed by autologous or allogeneic hematopoietic stem cell transplantation, combined with systematic prevention and treatment of meningeal leukemia and post-transplantation maintenance/immunotherapy as the overall treatment strategy and plan for adult ALL, and the 5-year leukemia-free survival (LFS) of patients who have completed the overall treatment has reached 60.5%±12.5%. This is the most systematic set of protocols for treating adult ALL in China so far, and the efficacy is at the leading level in China and reaches the international advanced level.

Chronic Lymphocytic Blood Disease (CLL): The center has recently conducted a follow-up analysis of nearly 400 cases of CLL diagnosed and treated in our hospital from 1980 to 2006, reporting the largest series of CLL cases in China, and discovering some of the clinical and biological features of CLL in our country, which lays a very good foundation for further basic and clinical research on CLL.

The center has a high-quality medical team with more than 20 doctors, including 2 chief physicians, 3 deputy chief physicians, 5 attending physicians, 10-12 residents, and more than 70% of the doctors have master's degrees and doctoral degrees; a team of more than 30 nurses, including 6 nurse practitioners in charge, and more than 70% of the nurses have college and undergraduate degrees; and 3 laboratory research and technical personnel. Laboratory researchers and technicians are 3 persons. There is 1 doctoral supervisor, 8 doctoral students and 6 master's students.

The center, as a model department of holistic care in hematology hospitals, has made many pioneering efforts in establishing a holistic care model for hematology patients, which has been praised by patients, hospitals, Tianjin Nursing Association and higher leaders. The center actively carries out spiritual civilization construction and creates "Youth Civilization" activities, and was awarded the national "Youth Civilization" by the Central Committee of the Youth League and the Ministry of Health in 2005.

The Lymphoma Diagnosis and Treatment Center is currently responsible for the research of "key technology of umbilical cord blood hematopoietic stem cell transplantation", "the expression and significance of -caterin in malignant hematological diseases", "cellular and molecular genetics and prognosis of multiple myeloma", and "the development of the cellular and molecular genetics and prognosis of multiple myeloma". In addition, we are also conducting clinical studies on imatinib (Gleevec) for Ph+ acute lymphoblastic leukemia, bortezomib (Vanco) combined with autologous hematopoietic stem cell transplantation, and rituximab (Merovia) combined with chemotherapy or hematopoietic stem cell transplantation for the treatment of B-cell non-Hodgkin's lymphoma.

Children's Hematology Center

Children's Hematology Center focuses on the pathogenesis, diagnosis, and treatment of various children's hematologic diseases, and develops systematic diagnostic and treatment programs according to different types of children's hematologic diseases, which are regularly revised and improved according to the principle of evidence-based medicine.

The Children's Hematology Center consists of two wards*** with more than 80 treatment beds, including 6 thousand-level laminar-flow isolation beds, which are used for the treatment of various children's hematological diseases, including various children's acute leukemias, children's bone marrow failure diseases, and so on.

The Children's Hematology Center carries out the following research:

1. Characteristics of extramedullary infiltration of childhood acute leukemiaThe research study found that extramedullary infiltration of children with acute lymphoblastic leukemia (ALL) is most common in mediastinal infiltration among the first diagnosed patients, and is mostly seen in children with T - ALL. The most common sites of extramedullary infiltration at the initial diagnosis of childhood AML were the CNS, skin, eyes, and pleura, and they occurred most frequently in children with t (8;21) chromosome abnormality of M2, M4, and M5 types. CNS infiltration was more common in AML than in ALL at the time of initial diagnosis, with a median age of 12 years, and was more frequent in males with high leukocytes. CNS infiltration was most common in M2 children with t (8 ;21) abnormalities. Extramedullary relapses during treatment were predominantly in the CNSL of children with ALL, with a prevalence of 14.5 %. This result suggests that extramedullary infiltration of acute leukemia in children and adolescents is more frequent in children with T- ALL and M2 with t (8;21) chromosome abnormality, and is associated with a poor prognosis. It provides a theoretical basis for the early intensive treatment of children with these types of leukemia, reduces extramedullary relapse, and improves the disease-free survival rate.

2. Cytogenetic study of childhood acute lymphoblastic leukemia The results of t(12;21) and TEL2AML1 fusion gene testing of bone marrow or peripheral blood nucleated cells of children with ALL using conventional karyotyping (CCA), interphase fluorescence in situ hybridization (I2FISH) and RT2PCR revealed that t(12;21) chromosome abnormality is the most common chromosomal abnormality in childhood ALL. the most common chromosomal translocation in childhood ALL in China. It is a non-T-cell lineage immunophenotype, mainly common type ALL, mostly accompanied by the loss of TEL allele, and the clinical manifestations and recent therapeutic efficacy are not significantly different from those of other non-T-cell lineage childhood ALL. The clinical manifestations and recent treatment outcome were not different from other non-T-cell lineage ALL in children. The characteristics of the children were different from those reported abroad: older age of onset, low m-platelet count and IgH rearrangement rate, and normal karyotype. The comparative analysis of children with Ph chromosome-positive ALL (Ph+ cALL) and adults with Ph chromosome-positive ALL (Ph+ aALL) for the first time led to the conclusion that Ph chromosome-positive children and adults with ALL have similar biological characteristics, and that the difference in prognostic impact of CD34 expression in the adult group versus the overall patient group could indirectly reflect the factors related to prognosis of Ph+ aALL and cALL. The conclusion of the differences.

3. Clinical efficacy of childhood acute leukemia

Based on the work of cytomorphology, immunology, cytogenetics and molecular biology (MICM), risk grouping treatment of childhood ALL was carried out, and the overall complete remission rate reached more than 95%, with the 3-year EFS and OS in the standard-risk group being 91.5% and 84.5%, respectively; and in the high-risk group the 3-year EFS and OS were 55.6% and 73.9%, respectively, which were comparable to the results reported internationally. Treatment of childhood acute myeloid leukemia was grouped according to cytogenetic abnormalities. Intensive (anthracycline alone) treatment with reduced toxicity was used for AML with t(15;17) translocation (low-risk group), with a total treatment period of 12 months, a 5-year cumulative relapse rate of 16%, and the main cause of treatment failure was early death due to concomitant leukocytosis and coagulation abnormality; the 5-year cumulative EFS, DFS, and OS were 72.3%, 85.0%, and 85.8%, respectively, and the overall The 5-year cumulative EFS, DFS, and OS were 72.3%, 85.0%, and 85.8%, respectively, with a significant reduction in treatment costs and a remarkable quality of survival. Early intensive treatment of AML with t(8;21) translocation (intermediate-risk group) resulted in a 4-year EFS, DFS, and OS of (25.9 ± 9.6)%, (28.4 ± 10.4)%, and (37.9 ± 10.3)%, respectively. The above information represents a larger number of cases in studies on childhood myeloid leukemia, and the results of these works are at the best level of international reporting.

In addition, the center has carried out ATG combined immunotherapy for severe aplastic anemia with an effective rate of 80%. Over the years, it has treated many cases of difficult pediatric hematological diseases, such as CDA (Childhood Dyserythropoietic Anemia) and Childhood Hepatosplenic γδ T-cell Lymphoma.

Children's Hematology Center has a first-class, high-quality medical team with expertise in pediatrics and hematology in China. There are 1 chief physician, 2 deputy chief physicians, 4 attending physicians, 10 residents and 6 master's degree holders. There is 1 doctoral supervisor. Nursing team 28 people. There are 2 people studying for doctoral degree and 3 people studying for master's degree.

Currently, the department is responsible for the research projects of "Comparative proteomic analysis of the prognosis of children's acute lymphoblastic leukemia", "Diagnosis of children's hematological diseases, standardized treatment, and prognosis assessment research" and other scientific research projects.